E-MEXP-3916 - A Pre-clinical model of induction therapy and relapse in pediatric acute lymphoblastic leukemia
Released on 1 November 2013, last updated on 2 June 2016
The development of a clinically relevant xenograft model of pediatric acute lymphoblastic leukemia, using a 4-drug treatment regimen designed to mimic pediatric remission induction therapy. Relapse and acquired drug resistance in T-cell acute lymphoblastic leukemia (T-ALL) remains a significant clinical problem. This study was designed to establish a preclinical model of resistance to induction therapy in childhood T-ALL to examine the emergence of drug resistance and identify novel therapies. We performed transcription profiling by array of human CD45-positive human lymphocytes from patients with acute pediatric lymphoblastic leukemia, and from xenografted NOD/SCID mice treated with vincristine, daunorubicin, dexamethasone and L-asparagine. Several different treatment regimes were used in this study (VLXD, VLXDR, VLXD2, VXL and VLXD2-ALL31) and are summarised in the protocols associated with this submission.
transcription profiling by array, co-expression, compound treatment design, in vivo
A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia. A L Samuels, A H Beesley, B D Yadav, R A Papa, R Sutton, D Anderson, G M Marshall, C H Cole, U R Kees and R B Lock. , Europe PMC 25083816